IAIon Anghelescu

Ion Anghelescu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ion Anghelescu has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Psychostimulants

    by Ion-George Anghelescu, Eike Ahlers

  • Antidepressant Drugs

    by Ion-George Anghelescu, Isabella Heuser

  • Psychostimulants

    by Ion-George Anghelescu, Eike Ahlers


  • Antidepressant Drugs

    by Ion-George Anghelescu, Isabella Heuser


  • Methadone for prisoners

    by Ion Anghelescu

    • 1 September 2013
      • Vol. 25  (3) , 214-20

    Quetiapine as combination treatment with citalopram in unipolar depression with prominent somatic symptoms: a randomised, double-blind, placebo-controlled pilot study.

    by Arnim Quante, Francesca Regen, Frank Schindler, Klaus Volkmer, Emanuel Severus, Carsten Urbanek, Alexander Luborzewski, Stefan Roepke, Ion Anghelescu

    Patients with major depressive disorder (MDD) accompanied by physical symptoms may be less responsive to antidepressant treatment. Quetiapine has been evaluated in the treatment of bipolar depression and has been recently approved as an add-on therapy for unipolar depression. Less is known about the efficacy of combination therapies in patients suffering from MDD with somatic symptoms. The aim of the present study was to evaluate the efficacy of quetiapine as adjunctive therapy to the SSRI citalopram in patients with MDD and somatic complaints. 41 inpatients with nonpsychotic DSM-IV MDD experiencing significant symptoms of somatic distress as defined by a baseline score on the SCL-90-R somatization subscale greater one standard deviation above adult nonpatient norms were randomly assigned to receive either citalopram 40 mg/day plus placebo (n=20) or citalopram 40 mg/day plus quetiapine, 300 to 600 mg/day (n=21) for 6 weeks. The primary outcome measure was the Hamilton Depression Rating Scale (HDRS) score. Mean changes in HDRS scores from baseline to week 6 using last-observation-carried-forward methods were -12.3±6.2 and -10.7±5.1 in the citalopram-quetiapine and citalopram-placebo group, respectively. Remission rates were significant higher in the citalopram-quetiapine-group (41.1%) than in the citalopram-placebo-group (26.3%), respectively. Although quetiapine as add-on to citalopram did not separate statistically from placebo on the HDRS score in improving depressive symptoms and somatic symptoms in patients with MDD and prominent somatic complaints, higher remission rates and other second outcome parameters showed advantages for quetiapine. Larger, double-blind, placebo-controlled trials of quetiapine as augmentation therapy in MDD with somatic symptoms are warranted.


    • 1 September 2013
      • Vol. 25  (3) , 227-35

    Childhood maltreatment and adult proinflammatory status in patients with major depression.

    by Sara Zeugmann, Nicole Buehrsch, Malek Bajbouj, Isabella Heuser, Ion Anghelescu, Arnim Quante

    An increasing body of research considers the immunological effects of major depression. It remains an open question, whether depression itself acts in an immunomodulatory fashion or whether other factors related to depression result in these immunological effects. Regardless, major depression is often the result of early life stress, the implications of which are not satisfactorily understood. Early life stress was retrospectively evaluated in 25 depressed inpatients via the CTQ (Childhood Trauma Questionnaire). Its impact on immunological biomarkers (fibrinogen, SAA, CRP, adiponectin, TNF-α, resistin, and sE-selectin) in adulthood was assessed via multiple regression analyses. Parental bonding was assessed via the PBI (Parental bonding questionnaire), severity of depression with the HDRS-17 (Hamilton-Depression-Rating Scale). Nearly all patients had experienced a parental style of affectionless control. Physical neglect significantly predicted fibrinogen levels (R(2)=0.42, adjusted R(2)=0.27, β=0.56, p=0.04). Severity of depression was not associated with immune markers. Childhood maltreatment was linked to fibrinogen levels in our sample. Thus, inflammation may be an important mechanism mediating the adverse effects of early life stress on adult health in patients with major depression.


  • Does early improvement predict response to the fast-dissociating D2 receptor antagonist JNJ-37822681 in patients with acute schizophrenia? ☆

    by Ion-George Anghelescu, Luc Janssens, Justine Kent, Peter de Boer, Luc Tritsmans, Ella J. Daly, Luc van Nueten, Mark E. Schmidt


    • 1 March 2012
      • Vol. 24  (1) , 57-65

    Pathways linking early life stress, metabolic syndrome, and the inflammatory marker fibrinogen in depressed inpatients.

    by Sara Zeugmann, Arnim Quante, Louchka Popova-Zeugmann, Wolfgang Kössler, Isabella Heuser, Ion Anghelescu

    Previous research has shown that metabolic syndrome as well as early life stress can account for immunoactivation (e.g. in the form of altered fibrinogen levels) in patients with major depression. This study aims at assessing the relationship between components of metabolic syndrome, early life stress and fibrinogen levels, taking the severity of depression into consideration. Measures of early life stress and signs of metabolic syndrome were collected in 58 adult inpatients diagnosed with depression. The relationships between the factors were assessed by means of path analyses. Two main models were tested: the first model with metabolic syndrome mediating between early life stress and fibrinogen levels and the second model without the mediating effect of metabolic syndrome. The first model was not supported by our data (χ²=7.02, df=1, p=0.008, CFI=0.00, NNFI=-9.44, RMSEA=0.50). The second model however provided an excellent fit for the data (χ²=0.02, df=1, p=0.90, CFI=1.00, NNFI=2.71, RMSEA=0.00). Extending the models by introducing severity of depression into them did not yield good indices of fit. The developmental trajectory between early life stress and inflammation appears not to be mediated by metabolic syndrome associated factors in our sample. Possible reasons including severity and type of early life stress, as well as potential epigenetic influences are discussed.